摘要
Introduction:Eosinophilia is a rare disease characterized by an increase in eosinophils.Suplatast tosilate is a selective Th2 cytokine inhibitor that can reduce eosinophils.There is currently a lack of clinical studies of suplatast tosilate in the treatment of eosinophilia.Research objective:To explore whether suplatast tosilate can reduce blood eosinophil levels in eosinophilia and the factors that might influence the improvement.Methods:A real-world retrospective study of 20 patients with eosinophilia was conducted using electronic medical record information.The main outcome measure was the difference in peripheral blood absolute eosinophil count(AEC)and percentage(EOS%)before suplatast tosilate(baseline)and the lowest AEC during the 1-year period of suplatast tosilate treatment(post-treatment).Data on age,gender,disease duration,involved organs,and concomitant medication were collected,and subgroup analysis and linear regression analysis were performed.Results:Subjects were predominantly male,with a mean age of 33 years and a disease duration of approximately 30 months.After treatment with suplatast tosilate,the patient's AEC(p=0.029)and EOS%(p=0.016)significantly decreased.The decline in eosinophils was more pronounced in patients who were male,age<33 years,disease duration<30 months and gastrointestinal system involvement.In addition,the shorter the course of the disease,the greater the relative decrease in eosinophils after suplatast tosilate treatment(β=-0.018,p<0.001).Conclusions:Suplatast tosilate is effective in reducing peripheral blood eosinophil levels in patients with eosinophilia.Large-scale prospective cohort studies are needed for further confirmation.
基金
supported by Clinical Research Operating Fund of Central High Level Hospitals(2022-PUMCH-D-002).
